Promising efficacy data in combination with KEYTRUDA® (pembrolizumab ... Two grade three adverse events related to BT-001 were reported (one skin ulcer and one lymphocyte count decrease). No DLTs were ...
BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients. Promising efficacy ...
BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with KEYTRUDA® (pembrolizumab) showed promising efficacy data ...
Canker sores are small mouth ulcers that usually form on the gums. Knowing how to get rid of canker sores with home remedies and over-the-counter treatments can limit pain and discomfort. Also called ...
After proving acellular matrices are effective in treating diabetic foot ulcers, researchers are now eyeing the treatment as a tool for healing venous leg ulcers. Typically, VLU treatment includes ...
Merck’s Keytruda Combo for Urothelial Carcinoma Gets EU Approval: The European Commission granted approval to Merck’s Keytruda in combination with Astellas/Pfizer’s antibody-drug conjugate ...
Using over-the-counter NSAIDs for the occasional headache or achy back won’t typically cause a peptic ulcer. Rather, peptic ulcer disease is something that can occur with longer-term use of NSAIDs, ...
(RTTNews) - IO Biotech (IOBT) announced that the Independent Data Monitoring Committee found the data from the Pivotal Phase 3 Trial of IO102-IO103 in combination with KEYTRUDA (pembrolizumab ...
Merck MRK decided to discontinue two separate phase III studies, KEYNOTE-867 and KEYNOTE-630, evaluating its blockbuster drug Keytruda in patients with certain types of lung cancer and skin cancer ...
London: Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial ...
Merck said Thursday morning it is discontinuing two Phase 3 trials of Keytruda, the world’s top-selling medicine, after independent data monitoring … ...